Pertuzumab Injection: Advanced HER2-Dimerization Inhibitor for Targeted Oncology – Global Supply by Ernest Oncology
In the precision medicine landscape of 2026, Pertuzumab Injection remains a cornerstone in the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) positive malignancies. As a recombinant humanized monoclonal antibody, Pertuzumab represents a sophisticated class of targeted therapy—HER2-dimerization inhibitors (HDIs)—designed to disrupt the signaling pathways that drive aggressive tumor proliferation.
Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Pertuzumab to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, providing end-to-end cold-chain solutions and rigorous documentation for global medical procurement.
Technical Product Profile: Pertuzumab Injection
Pertuzumab is a biological agent that targets the extracellular domain of the HER2 protein, specifically preventing it from pairing with other members of the HER family.
Product Specifications
Active Ingredient: Pertuzumab
Concentration: 420 mg / 14 mL (30 mg/mL) Single-dose Vial
Pharmacological Class: HER2-Dimerization Inhibitor (Monoclonal Antibody)
Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Do not freeze.
Primary Clinical Indications
Metastatic Breast Cancer (MBC): Indicated for use in combination with Trastuzumab and Docetaxel for patients with HER2-positive MBC who have not received prior anti-HER2 therapy.
Neoadjuvant Treatment: For patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen.
Adjuvant Treatment: For patients with HER2-positive early breast cancer at high risk of recurrence.
Mechanism of Action: The Science of Dimerization Blockade
Pertuzumab’s therapeutic efficacy lies in its ability to target the HER2 dimerization domain (Domain II).
Prevention of Heterodimerization: Pertuzumab inhibits the ligand-induced pairing of HER2 with other HER receptors, most notably HER3. This pairing is the most potent signaling driver for cancer cell survival.
Dual Blockade Synergy: When used with Trastuzumab, which binds to Domain IV, the two antibodies provide a comprehensive "Dual Blockade," shutting down both ligand-dependent and ligand-independent growth signals.
Antibody-Dependent Cellular Cytotoxicity (ADCC): Pertuzumab marks the cancer cells for destruction by the body’s innate immune system, specifically natural killer (NK) cells.
Global Export Excellence: UK, USA, UAE, Australia, & South Africa
Ernest Oncology manages the logistical complexities of shipping temperature-sensitive biologicals from India to the world’s most demanding healthcare markets.
United Kingdom & London: We supply NHS trusts and private oncology centers in London, adhering to all MHRA biological import protocols and safety standards.
United States: Bulk supply for hospital systems and specialty wholesalers seeking verified Indian pharmaceutical exports for advanced HER2+ therapy.
Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with fast-track, secure, temperature-monitored shipping.
Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological import standards.
South Africa: Strengthening the African oncology sector with high-quality, cost-effective targeted therapies from GMP facilities.
📞 Contact Ernest Oncology — Pharmaceutical Exporter from India
(Group of Ernest Pharmaceutical Pvt. Ltd.)
Partner with a verified leader for the bulk procurement of oncology injectables and specialized biological products.
🌐 Websites:
📧 Email:
📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp: +91 93599 02383
🔗 Instant Chat:
